Disruption or technological Innovation, Hope and Progress, Personalized Medicine aims to “give the right treatment to the right patient”

ACOBIOM is seeking financial partners interested in sharing its ambitions and its objective to commercialize Diagnostics dedicated to Personalized Medicine in the treatments of Cancers and Nervous System (Alzheimer’s disease…).

 

Based on Blood Biomarkers (circulating biomarkers from liquid biopsy), ACOBIOM develops innovative Diagnostics dedicated to Personalized Medicine, an expanding field and market estimated to be worth $2.5tn in 2022 (Genetic Insider, 2016).

These diagnostics (cf pipeline below) are associated to the treatments of Cancers and Nervous System (Alzheimer’s disease…). They have been developing for routine uses on platforms labeled and used in hospitals and central laboratories

Acobiom Pipeline 13032017 EN web

Hence, ACOBIOM is present on two growing markets:

> Biomarkers: market evaluated at US$ 53.3B in 2021 presenting a 13.8% growth on the 2016-2021 period (source: Markets & Markets);
> Companion Diagnostics Compagnons: market evaluated at US$ 6,5B in 2022 presenting a 20.1% growth on the 2017-2022 period (source: Markets & Markets).

Financial partners, interested in sharing the ambitions and the objective of ACOBIOM to commercialize Diagnostics dedicated to Personalized Medicine, and in particular the GemciTest in 2019, can contact the company to read the Executive Summary and the documents dedicated to investors.

To obtain more information about ACOBIOM, its Diagnostic pipeline, and about the seeking funds in 2017 & 2018, please contact Philippe Outrebon (info@acobiom.com, T: +33(0)467 419 748).